ES2321687T3 - Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor. - Google Patents

Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor. Download PDF

Info

Publication number
ES2321687T3
ES2321687T3 ES00989877T ES00989877T ES2321687T3 ES 2321687 T3 ES2321687 T3 ES 2321687T3 ES 00989877 T ES00989877 T ES 00989877T ES 00989877 T ES00989877 T ES 00989877T ES 2321687 T3 ES2321687 T3 ES 2321687T3
Authority
ES
Spain
Prior art keywords
cells
isolated
antibody
nkp30
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00989877T
Other languages
English (en)
Spanish (es)
Inventor
Alessandro Moretta
Cristina Bottino
Roberto Biassoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Original Assignee
Innate Pharma SA
DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2288307A external-priority patent/CA2288307C/en
Application filed by Innate Pharma SA, DIMES Dipartimento di Medicina Sperimentale Universita degli Studi di Genova filed Critical Innate Pharma SA
Application granted granted Critical
Publication of ES2321687T3 publication Critical patent/ES2321687T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES00989877T 1999-11-15 2000-11-15 Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor. Expired - Lifetime ES2321687T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44051499A 1999-11-15 1999-11-15
CA2288307 1999-11-15
US440514 1999-11-15
CA2288307A CA2288307C (en) 1999-11-15 1999-11-15 Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

Publications (1)

Publication Number Publication Date
ES2321687T3 true ES2321687T3 (es) 2009-06-10

Family

ID=25681295

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00989877T Expired - Lifetime ES2321687T3 (es) 1999-11-15 2000-11-15 Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor.

Country Status (8)

Country Link
EP (1) EP1240326B1 (https=)
JP (1) JP4776845B2 (https=)
AT (1) ATE423848T1 (https=)
AU (1) AU783899B2 (https=)
DE (1) DE60041655D1 (https=)
DK (1) DK1240326T3 (https=)
ES (1) ES2321687T3 (https=)
WO (1) WO2001036630A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
WO2004056392A1 (en) * 2002-12-23 2004-07-08 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005105848A1 (en) * 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
WO2006009731A1 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Methods of using apo2l receptor agonists and nk cell activators
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
EP1626059A1 (en) * 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
KR101662622B1 (ko) * 2007-10-04 2016-10-05 지모제넥틱스, 인코포레이티드 Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
AU2016299166B2 (en) * 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
AU2018371114A1 (en) 2017-11-21 2020-05-07 Innate Pharma Multispecific antigen binding proteins
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4448095A1 (en) 2021-12-14 2024-10-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP7821427B2 (ja) * 2022-01-27 2026-02-27 学校法人 東洋大学 ナチュラルキラー細胞活性の測定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502089A (ja) * 1993-08-27 1997-03-04 ダナ−ファーバー キャンサー インスティチュート インコーポレイテッド ナチュラルキラー細胞特異性抗原およびこの抗原を識別する抗体
ZA9810133B (en) * 1997-11-07 1999-05-17 Biogen Inc BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes
US7396681B1 (en) * 1998-03-27 2008-07-08 Gabriele Multhoff Application of Hsp70 proteins

Also Published As

Publication number Publication date
WO2001036630A9 (en) 2002-09-19
DK1240326T3 (da) 2009-06-02
JP2003523735A (ja) 2003-08-12
EP1240326A2 (en) 2002-09-18
ATE423848T1 (de) 2009-03-15
WO2001036630A2 (en) 2001-05-25
AU783899B2 (en) 2005-12-22
JP4776845B2 (ja) 2011-09-21
DE60041655D1 (de) 2009-04-09
EP1240326B1 (en) 2009-02-25
AU2667701A (en) 2001-05-30
WO2001036630A3 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
ES2321687T3 (es) Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor.
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
JP7539434B2 (ja) トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP7303314B2 (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
JP6133209B2 (ja) 抗ｓｓｘ−２ｔ細胞受容体及び関連材料並びに使用方法
Perussia et al. Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene.
ES2279585T3 (es) Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso.
PT726952E (pt) Receptor na superfície de células t activadas: act-4
JPH09509826A (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
Söderström et al. High expression of V gamma 8 is a shared feature of human gamma delta T cells in the epithelium of the gut and in the inflamed synovial tissue.
US6946255B1 (en) Monoclonal antibody reacting specifically reacting with Fas ligand and production process thereof
JPWO1996029350A1 (ja) Ｆａｓリガンドに特異的に反応するモノクローナル抗体及びその製造方法
US7138243B2 (en) NTB-A, a surface molecule involved in natural killer cells activity
AU2002325333A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
US20080248045A1 (en) Polypeptides having a triggering nk activity and biological applications
Struijk et al. Inflamed joints of patients with rheumatoid arthritis contain T cells that display in vitro proliferation to antigens present in autologous synovial fluid functional analysis on the basis of synovial-fluid-reactive T-cell clones and lines
CA2288307C (en) Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
US5646251A (en) Alloreaction-associated antigen (ARAG): a novel member of the immunoglobulin gene superfamily
Morelli et al. Triggering of the cytotoxic activity of murine natural killer and lymphokine-activated killer cells through the NK2. 1 antigen.
Smith Expression, function and ligands for the Ly-49H NK cell activation receptor
Mehta Allelic variation and “chimerism” of Ly49 natural killer cell receptors